|
|
Vaccine Detail
|
WT1 235-243 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: WT1 235-243 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007058
- Type: Peptide Vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: WT1
- WT1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Cell line derived from a blast crisis of chronic myeloid leukemia was used to express WT1235 peptide (Tamanaka et al., 2012).
- Description: This is for Leukemia Cancer and Solid Tumors. A synthetic peptide vaccine consisting of a HLA-A24-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 235 through 243, a MHC class I-restricted peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 235-243 peptide may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers (Tamanaka et al., 2012; NCIT_C104734).
|
| Host Response |
|
|
| References |
NCIT_C104734: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104734]
Tamanaka et al., 2012: Tamanaka T, Oka Y, Fujiki F, Tsuboi A, Katsuhara A, Nakajima H, Hosen N, Nishida S, Lin YH, Tachino S, Akatsuka Y, Kuzushima K, Oji Y, Kumanogoh A, Sugiyama H. Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor. Anticancer research. 2012; 32(12); 5201-5209. [PubMed: 23225417].
|
|
